First confirmed non-fatal cychlorphine overdose found in patient blood

The American College of Medical Toxicology says a case report in the Journal of Medical Toxicology provides the first biologically confirmed non-fatal overdose tied to cychlorphine, a synthetic opioid not detected by routine hospital testing. The finding underscores how emerging opioids can hide in counterfeit pills and complicate overdose care.

Why it matters: - The case offers the first direct biological evidence that cychlorphine can cause a non-fatal overdose in a patient. - Routine hospital toxicology tests missed the opioid, highlighting a gap that can slow recognition of emerging drug threats. - The report reinforces that clinicians should treat suspected opioid overdose based on symptoms, not just screening results.

What happened: - The American College of Medical Toxicology announced a case report published in the Journal of Medical Toxicology. - A woman arrived at an emergency department after reportedly taking alprazolam. - She developed respiratory depression and improved after naloxone was given. - Routine toxicology testing was negative for fentanyl and other opioids. - Advanced analysis of a blood specimen identified cychlorphine as the only opioid detected.

The details: - Cychlorphine is a potent synthetic opioid in the “orphine” class. - The drug has emerged in the illicit supply and has already been found in fatal overdose cases. - Until now, clinical information about cychlorphine exposure in survivors had been limited. - The new case differs from earlier reports that relied on drug material recovered at the scene. - The case came through the Toxicology Investigators Consortium Fentalog Study, a multicenter surveillance program tracking emergency department patients with suspected opioid overdose. - Cychlorphine is structurally distinct from fentanyl and is not detected by standard hospital toxicology assays. - The patient’s report of alprazolam raises concern that a counterfeit pill may have contained cychlorphine. - Rebecca Kusko, MD, said the case shows the need for comprehensive drug surveillance and advanced toxicological testing to identify substances that may otherwise go undetected.

Between the lines: - The case suggests that the illicit drug supply is evolving faster than routine hospital testing can keep up. - It also points to a broader surveillance problem: a patient can present with a classic opioid toxidrome while standard testing still appears negative. - That mismatch can delay recognition of novel synthetic opioids in both emergency care and public health monitoring.

What's next: - ACMT says the findings support expanded use of advanced toxicology methods in overdose investigations. - The ToxIC Fentalog Study will continue adding national surveillance data on emerging drugs. - The report may help clinicians and toxicologists better identify future cases involving novel synthetic opioids. - More information is available in the full study and ACMT media inquiries.

The bottom line: - Cychlorphine can produce a real overdose that routine hospital tests may miss, making advanced testing and symptom-based treatment more important.